Literature DB >> 22131327

Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Simona Zompi1, Brian H Santich, P Robert Beatty, Eva Harris.   

Abstract

The four dengue virus (DENV) serotypes cause dengue fever and dengue hemorrhagic fever/dengue shock syndrome. Although severe disease has been associated with heterotypic secondary DENV infection, most secondary DENV infections are asymptomatic or result in classic DF. The role of cross-reactive immunity in mediating cross-protection against secondary heterotypic DENV infection is not well understood. DENV infection of IFN-α/β and IFN-γ receptor-deficient (AG129) mice reproduces key features of human disease. We previously demonstrated a role in cross-protection for pre-existing cross-reactive Abs, maintained by long-lived plasma cells. In this study, we use a sequential infection model, infecting AG129 mice with DENV-1, followed by DENV-2 6-8 wk later. We find that increased DENV-specific avidity during acute secondary heterotypic infection is mediated by cross-reactive memory B cells, as evidenced by increased numbers of DENV-1-specific cells by ELISPOT and higher avidity against DENV-1 of supernatants from polyclonally stimulated splenocytes isolated from mice experiencing secondary DENV-2 infection. However, increased DENV-specific avidity is not associated with increased DENV-specific neutralization, which appears to be mediated by naive B cells. Adoptive transfer of DENV-1-immune B and T cells into naive mice prior to secondary DENV-2 infection delayed mortality. Mice depleted of T cells developed signs of disease, but recovered after secondary DENV infection. Overall, we found that protective cross-reactive Abs are secreted by both long-lived plasma cells and memory B cells and that both cross-reactive B cells and T cells provide protection against a secondary heterotypic DENV infection. Understanding the protective immunity that develops naturally against DENV infection may help design future vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22131327      PMCID: PMC3244532          DOI: 10.4049/jimmunol.1102124

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG.

Authors:  H Leyendeckers; M Odendahl; A Löhndorf; J Irsch; M Spangfort; S Miltenyi; N Hunzelmann; M Assenmacher; A Radbruch; J Schmitz
Journal:  Eur J Immunol       Date:  1999-04       Impact factor: 5.532

Review 2.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

3.  The dengue group of viruses and its family relationships.

Authors:  A B SABIN
Journal:  Bacteriol Rev       Date:  1950-09

4.  Risk factors in dengue shock syndrome.

Authors:  S Thein; M M Aung; T N Shwe; M Aye; A Zaw; K Aye; K M Aye; J Aaskov
Journal:  Am J Trop Med Hyg       Date:  1997-05       Impact factor: 2.345

5.  Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study.

Authors:  M G Guzmán; G P Kouri; J Bravo; M Soler; S Vazquez; L Morier
Journal:  Am J Trop Med Hyg       Date:  1990-02       Impact factor: 2.345

6.  Antibody-enhanced dengue virus infection in primate leukocytes.

Authors:  S B Halstead; E J O'Rourke
Journal:  Nature       Date:  1977-02-24       Impact factor: 49.962

7.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

8.  Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever.

Authors:  Tadeusz J Kochel; Douglas M Watts; Scott B Halstead; Curtis G Hayes; Angelica Espinoza; Vidal Felices; Roxana Caceda; Christian T Bautista; Ysabel Montoya; Susan Douglas; Kevin L Russell
Journal:  Lancet       Date:  2002-07-27       Impact factor: 79.321

9.  A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.

Authors:  Fernando P Polack; Scott J Hoffman; Gonzalo Crujeiras; Diane E Griffin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

Review 10.  Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development.

Authors:  Theodore C Pierson; Daved H Fremont; Richard J Kuhn; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023

View more
  52 in total

1.  Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.

Authors:  Haiyan Chu; Subash C Das; Jeremy F Fuchs; M Suresh; Scott C Weaver; Dan T Stinchcomb; Charalambos D Partidos; Jorge E Osorio
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

2.  Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles.

Authors:  Yuan Tian; Mariana Babor; Jerome Lane; Grégory Seumois; Shu Liang; N D Suraj Goonawardhana; Aruna D De Silva; Elizabeth J Phillips; Simon A Mallal; Ricardo da Silva Antunes; Alba Grifoni; Pandurangan Vijayanand; Daniela Weiskopf; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

3.  Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells.

Authors:  Daniela Weiskopf; Michael A Angelo; Elzinandes L de Azeredo; John Sidney; Jason A Greenbaum; Anira N Fernando; Anne Broadwater; Ravi V Kolla; Aruna D De Silva; Aravinda M de Silva; Kimberly A Mattia; Benjamin J Doranz; Howard M Grey; Sujan Shresta; Bjoern Peters; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-11       Impact factor: 11.205

4.  Original antigenic sin in dengue revisited.

Authors:  Simona Zompi; Eva Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-16       Impact factor: 11.205

Review 5.  T Cell Immunity to Zika and Dengue Viral Infections.

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  J Interferon Cytokine Res       Date:  2017-11       Impact factor: 2.607

Review 6.  Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.

Authors:  Hui Xuan Lim; Jianhua Lim; Chit Laa Poh
Journal:  Med Microbiol Immunol       Date:  2021-01-30       Impact factor: 3.402

Review 7.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

8.  A Single Mutation in the VP1 of Enterovirus 71 Is Responsible for Increased Virulence and Neurotropism in Adult Interferon-Deficient Mice.

Authors:  Elizabeth A Caine; Louise H Moncla; Monica D Ronderos; Thomas C Friedrich; Jorge E Osorio
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

9.  Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients.

Authors:  Tatiana M Garcia-Bates; Marli T Cordeiro; Eduardo J M Nascimento; Amanda P Smith; Klécia M Soares de Melo; Sean P McBurney; Jared D Evans; Ernesto T A Marques; Simon M Barratt-Boyes
Journal:  J Immunol       Date:  2012-11-30       Impact factor: 5.422

10.  Evaluation of Commercially Available Assays for Diagnosis of Acute Dengue in Schoolchildren During an Epidemic Period in Medellin, Colombia.

Authors:  Leidy D Piedrahita; Ivony Y Agudelo; Andrea I Trujillo; Ruth E Ramírez; Jorge E Osorio; Berta N Restrepo
Journal:  Am J Trop Med Hyg       Date:  2016-05-16       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.